Haleon plc (NYSE:HLN) Shares Acquired by Banco Santander S.A.

Banco Santander S.A. raised its stake in shares of Haleon plc (NYSE:HLN) by 54.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 129,200 shares of the company’s stock after purchasing an additional 45,300 shares during the period. Banco Santander S.A.’s holdings in Haleon were worth $1,367,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Sculptor Capital LP increased its holdings in shares of Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after buying an additional 3,592,000 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Haleon by 8.6% in the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock worth $344,888,000 after purchasing an additional 3,307,009 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Haleon by 95.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock valued at $16,143,000 after purchasing an additional 954,622 shares in the last quarter. Natixis Advisors LLC grew its holdings in shares of Haleon by 142.5% during the 3rd quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after purchasing an additional 866,070 shares during the period. Finally, Raymond James & Associates increased its position in Haleon by 14.7% during the 2nd quarter. Raymond James & Associates now owns 4,019,978 shares of the company’s stock worth $33,205,000 after purchasing an additional 515,651 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of HLN stock opened at $9.65 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company’s fifty day moving average price is $10.03 and its two-hundred day moving average price is $9.37. The firm has a market capitalization of $43.68 billion, a P/E ratio of 28.38, a P/E/G ratio of 2.86 and a beta of 0.30. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Berenberg Bank assumed coverage on Haleon in a research note on Tuesday, August 6th. They set a “buy” rating on the stock. Finally, Morgan Stanley upped their target price on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.